Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders Proceedings of a Workshop (2022) / Chapter Skim
Currently Skimming:
2 History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders
2 History and Current Status of Psychedelics and Entactogens for the Treatment of Psychiatric Disorders
Pages 9-16
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 9... ...
. • Lengthy screening assessments and preparatory visits with trained facilitators enable patients to feel safe during treatment 9
|
From page 10... ...
Wasson sent the mushrooms to leading chemists around the world, including Albert Hoffman, who, only a decade or so earlier, had discovered that the synthetic chemical lysergic acid diethylamide (LSD) exerted powerful psychoactive effects.
|
From page 11... ...
Unlike conventional psychopharmacologic compounds, which are typically administered on a daily basis for weeks, months, or years, psychedelics are administered only once or a few times within the context of ongoing psychotherapy, he said. Conventional agents are also intended to ameliorate a pathological brain state and are not dependent on the patient's attitude or insight, while psychedelics loosen defenses, facilitate insight, and may induce a mystical experience.
|
From page 12... ...
. According to Grob, "It's very difficult to put these experiences into words, endowing the user with a profound sense of meaning of their psychological and/or philosophical insight." MDMA is relatively mild, easily controlled, and of moderate duration, said Grob, and has "the unique quality of facilitating profound empathy and compassion toward oneself and others." Combined with its ability to facilitate insight, introspection, and positive mood, he said MDMA has been "found to be very valuable within a psychotherapeutic context." Looking to the future, Grob said optimizing safety and ethical p arameters is critical.
|
From page 13... ...
"I was desperate." Osowski went through the lengthy screening assessments, successfully enrolled, and began her preparatory visits with a social worker at Johns Hopkins who served as Osowski's session facilitator. During these visits, the social worker talked to her about her history and frame of mind and prepared her for what to expect in the trial.
|
From page 14... ...
She sought help from psychiatrists and other physicians, psychologists, social workers, therapists, physical therapists, an acupuncturist, a massage therapist, practitioners of deep-tissue bodywork known as Rolfing, and other alternative and homeopathic approaches to mental wellness. At times, she said, some of these modalities would temporarily relieve her symptoms, but "nothing really lasted, nothing addressed the core trauma." In 2017, after reading about a study exploring the use of MDMA for the treatment of PTSD, Tipton applied and was accepted to participate in the Multidisciplinary Association for Psychedelic Studies (MAPS)
|
From page 15... ...
"If that embodied experience of being with my brother was all I got out of the entire experience, it would have been completely worth it." She said she also recalled specifics about the murder scene at her mother's house that had been completely missing from her internal narrative of the event. "It wasn't like logically filling in the blank," but more like finding a section of a videotape that had been removed, she said.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.